UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer
Abstract
OBJECTIVES: To evaluate the activity of intravesical mitomycin C (MMC) to ablate recurrent low risk non-muscle invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. PATIENTS AND METHODS: CALIBER is a phase II feasibility study. Participants were randomised (2:1) to treatment with four once-weekly MMC 40mg intravesical instillations (chemoablation arm) or surgical management. The surgical group was included to assess feasibility of randomisation. The primary endpoint was complete response to intravesical MMC in the chemoablation arm at three months, reported with exact 95% confidence intervals. Secondary endpoints included time to subsequent recurrence, summarised by Kaplan-Meier methods. RESULTS: Between February 2015 and August 2017 82 patients with visual diagnosis of recurrent low risk NMIBC were enrolled from 24 UK hospitals (54 chemoablation, 28 surgical management). Median follow-up was 24 months. Complete response at three months was 37.0% (20/54; 95%CI: 24.3-51.3) with chemoablation and 80.8% (21/26; 95%CI 60.6-93.4) with surgical management. Amongst patients with complete response at three months, a similar proportion were recurrence-free by 12 months in both groups (84%). Amongst those with residual disease at three months, the 12-month recurrence-free proportion was lower in the surgical management group (40.0%) than in the chemoablation group (84%). Recruitment stopped early as chemoablation did not meet the pre-specified threshold of 45% complete responses at three months. CONCLUSION: Intravesical chemoablation in low risk NMIBC is feasible and safe, but did not demonstrate sufficient response in this trial. Following chemoablation there may be a reduction in recurrence rate, even in non-responders, that is greater than with surgery alone. Further research is required to investigate the role and optimal schedule of neo-adjuvant intravesical chemotherapy prior to surgery for NMIBC.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Department of Targeted Intervention
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by